SY
SYGGF.US Synairgen plc
- Market cap
- USD 110K
- P/E
- -
- P/B
- 0.01x
- ROE
- -100.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is SYGGF.US undervalued?
Graham numberThe Graham number of Synairgen plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Synairgen plc fundamental analysis
No fundamental analysis for Synairgen plc yet.
Synairgen plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Synairgen plc
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an investigative formulation of inhaled interferon beta (IFN-ß') for the treatment and prevention of severe viral lung infections in high-risk patient groups. The company was incorporated in 2003 and is headquartered in Southampton, the United Kingdom.
Full company profileSynairgen plc financial statements
Synairgen plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 5.03M | 105K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 |
| Gross Profit | - | 5.03M | 105K | -163K | -260K | -195K | -102K | -84.0K | -41.3K | - |
| Operating Income | -3.44M | 1.62M | -4.13M | -4.82M | -17.7M | -57.9M | -20.3M | -10.3M | -8.32M | -12.9M |
| EBITDA | -3.41M | 1.64M | -4.09M | -4.62M | -17.5M | -57.7M | -20.2M | -10.2M | -8.29M | -12.5M |
| Net Income | -2.82M | 1.76M | -3.30M | -3.89M | -13.9M | -48.7M | -17.6M | -8.41M | -6.81M | -12.1M |
| EPS | -0.03 | 0.02 | -0.03 | -0.04 | -0.09 | -0.24 | -0.09 | -0.04 | -0.03 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 5.55M | 7.66M | 6.80M | 4.07M | 88.5M | 44.6M | 23.5M | 14.2M | 7.82M | 14.6M |
| Total Liabilities | 860K | 1.10M | 777K | 1.82M | 3.41M | 7.64M | 3.25M | 1.56M | 1.54M | 2.53M |
| Shareholders' Equity | 4.69M | 6.56M | 6.03M | 2.25M | 85.1M | 37.0M | 20.3M | 12.7M | 6.28M | 12.1M |
| Cash & Short-term Investments | 4.77M | 6.85M | 5.33M | 2.45M | 75.0M | 33.8M | 19.7M | 12.0M | 4.55M | 12.5M |
| Total Debt | - | - | - | 328K | 128K | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.99M | 2.07M | -3.82M | -2.90M | -23.8M | -41.0M | -14.3M | -8.22M | -7.81M | -10.4M |
| Capital Expenditure | 5.00K | 6.00K | 386K | 10.0K | 76.0K | 33.0K | 6.00K | 13.0K | 94.0K | 210K |
| Free Cash Flow | -2.99M | 2.06M | -4.21M | -2.91M | -23.9M | -41.0M | -14.3M | -8.23M | -7.90M | -10.6M |
| Ratios | ||||||||||
| ROE | -60.1% | 26.8% | -54.8% | -172.4% | -16.3% | -131.5% | -87.0% | -66.4% | -108.5% | -100.3% |
| ROA | -50.8% | 23.0% | -48.5% | -95.4% | -15.7% | -109.0% | -75.0% | -59.1% | -87.1% | -83.0% |
| Net Profit Margin | - | 35.0% | -3,143.8% | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | 0.15x | 0.00x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Synairgen plc dividends
Synairgen plc has not paid dividends in the last 10 fiscal years.
Who owns Synairgen plc
- Insiders 0.57%
- Institutions 87.22%
- Public & others 12.21%
- Shares outstanding 1.10B
- Free float 143M
Synairgen plc company profile
- Company name
- Synairgen plc
- Ticker
- SYGGF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 34
- Fiscal year end
- December
- Address
- Mailpoint 810, Southampton, United Kingdom, SO16 6YD
- Phone
- 44 23 8051 2800
- Website
- synairgen.com
About Synairgen plc
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an investigative formulation of inhaled interferon beta (IFN-ß') for the treatment and prevention of severe viral lung infections in high-risk patient groups. The company was incorporated in 2003 and is headquartered in Southampton, the United Kingdom.
Synairgen plc management
9- Mr. Joseph Tregonning Colliver F.C.A.CEO & Executive Director · born 1980
- Prof. Stephen T. Holgate CBE, M.D.Co-Founder & Member of Scientific Advisory Board · born 1947
- Dr. Mark Parry-Billings Ph.D.Executive Chairman · born 1964
- Prof. Donna DaviesCo-Founder & Member of Scientific Advisory Board
- Prof. Ratko DjukanovicCo-Founder & Member of Scientific Advisory Board
- Andy LeeFinance Director
- Ms. Jody BrookesSenior VP & Head of Clinical Operations
- Dr. Marcin Mankowski M.D.CMO & Head of Scientific Affairs
- Mr. Simon William Holden Esq.Company Secretary · born 1976